The following is a summary of the Inari Medical, Inc. (NARI) Q3 2024 Earnings Call Transcript:

Financial Performance:

• Inari Medical reported a Q3 2024 revenue of $153.4 million, which is a 21% year-over-year growth.

• Gross margin for Q3 2024 was 87.1%, slightly down from the prior year due to product mix and ramp-up costs associated with new products.

• Operating expenses in Q3 2024 were $147.1 million, an increase primarily due to personnel-related expenses and a one-time non-cash impairment charge.

• Despite a GAAP operating loss of $13.6 million, the non-GAAP operating loss was $0.4 million, showing significant improvement and movement towards profitability.

Business Progress:

• Inari Medical continues to focus on driving adoption of its PE and DVT therapies and emerging therapies portfolio.

• Significant progress was made in the international business, with strong revenue growth driven by adoption in Europe and advances in regulatory approvals in Brazil, China, and Japan.

• Announced the commencement of a limited market release of the next-gen Artix system in acute limb ischemia, expected to serve a $600 million U.S. TAM.

• Introduced next-gen stent delivery system for LimFlow, aiming for broad commercialization in 2025, alongside enhanced inpatient and outpatient reimbursements.

Opportunities:

• Ongoing commercial and market development efforts are expected to drive robust growth in the U.S. and international markets, particularly with the awaiting PEERLESS study data, which could potentially shift front-line treatment standards in VTE care.

• Emerging therapies and international expansions signify strong growth potential, especially with regulatory progress in markets like China and Japan.

Risks:

• Growth from emerging therapies, such as Artix, expected to be gradual as these products undergo phased market introductions and gauging their market acceptance.

• The reliance on PEERLESS study outcomes to potentially influence rapid adoption and standard treatment protocols for PE.

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.